OQROGet OQRO Pro
Insider trade

Amgen (AMGN)Officer sold ~$376K

Matthew C. Busch, Officer at Amgen, sold ~$376K of Amgen shares.

~$376K
Approx. value · 1,000 sh @ $375.79
3,423
Holds after · shares reported
Traded
Feb 19, 2026
Filed
Feb 21, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  2. Nov 19, 2024CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  3. Jan 16, 2026CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  4. Jan 29, 2026CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  5. Jan 30, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
  6. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  7. Feb 17, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  8. Feb 19, 2026 · this disclosureInsiderOfficer sold ~$376K of AMGN shares in the open market

What came next

  1. Feb 26, 2026Insider · 1 personInsiders: 2 sales (~$20.8M)
  2. Feb 26, 2026CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  3. Mar 9, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  4. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  5. Mar 24, 2026CongressDisclosed purchase of AMGN — reported range $15,001 - $50,000
  6. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  7. Mar 31, 2026Government · Federal Register proposed ruleFiduciary Duties in Selecting Designated Investment Alternatives
  8. Apr 17, 2026CongressDisclosed sale of AMGN — reported range $15,001 - $50,000
  9. Apr 22, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer.”
  10. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  11. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
  12. Apr 30, 2026Government · Federal Register noticeChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing
  13. May 4, 2026InsiderOfficer sold ~$400K of AMGN shares in the open market
  14. May 14, 20265% stakeCapital World Investors reported a passive stake (13G) of 5.5%
  15. May 19, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026.”
  16. Jun 4, 2026FDARecall: Corlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. NDC 55513-810-60
  17. Jun 4, 2026FDARecall: Corlanor (ivabradine) tablets, 5 mg, packaged in a) 14 tablets bottles (NDC 55513-800-99), and b) 60 tablet bottles (NDC 55513-800-60), Rx Only, Amgen Inc., Th…
  18. Jun 4, 2026FDARecall: Sensipar (cinacalcet) Tablets, 60mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks ,CA 91320-1799, Made in Japan. NDC…
  19. Jun 4, 2026FDARecall: Sensipar (cinacalcet) Tablets, 90mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, Made in Japan. NDC…
  20. Jun 4, 2026FDARecall: Sensipar (cinacalcet) Tablets, 30mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks ,CA 91320-1799, Made in Japan. NDC…
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Amgen

For Amgen, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports and 75 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMGN page.

Other recent filings by Matthew C. Busch, VP, Finance & CAO

The full history of Matthew C. Busch, VP, Finance & CAO is on the profile page.

How this filing works

Other disclosures at Amgen

Everything OQRO holds on this company is on its AMGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data